Lantheus Medical Imaging
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Lantheus Medical Imaging sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Lantheus Medical Imaging: 22 sponsored US clinical trials, 2 recruiting.
Lantheus Medical Imaging sponsors 22 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 19 completed. 12 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed / Refractory Osteosarcoma, with 1 trials.
Top-decile sponsor footprint
Lantheus Medical Imaging ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
22 total, page 1 of 1
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
NCT07357519
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
NCT06074510
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
NCT03719612
DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
NCT03571672
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
NCT01347710
Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
NCT01135316
A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure
NCT00891241
A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure
NCT00918866
Study of [3H] BMS747158 in Healthy Male Subjects
NCT00930631
Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158
NCT00849108
Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®
NCT01299649
A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress
NCT00707538
A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice
NCT00625365
A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158
NCT00707499
DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function
NCT00401687
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
NCT00162032
CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI
NCT00162331
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
NCT00162045
A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
NCT00162370
Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00162357
A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.
NCT00162344
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Lantheus Medical Imaging pipeline
2 recruiting of 22 indexed (9% open); 19 completed (86%).
Phase mix: 12 late (III/IV) vs 8 early (I/II) (balanced across stages).
Top condition: Relapsed / Refractory Osteosarcoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lantheus Medical Imaging: open-pipeline peers nationwide
Peers matched on 22 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Lantheus Medical Imaging sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 trials (± recruiting share)
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Alkermes · 9% recruiting · 66 trials
- DBV Technologies · 9% recruiting · 11 trials
- Florida Gulf Coast University · 9% recruiting · 11 trials
- Genfit · 9% recruiting · 11 trials
Related
What to do with this Lantheus Medical Imaging page
22 registered trials is a research-attention snapshot, not an endorsement of Lantheus Medical Imaging or any single study.
- 2 of Lantheus Medical Imaging's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed / Refractory Osteosarcoma is the condition Lantheus Medical Imaging studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed / Refractory Osteosarcoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lantheus Medical Imaging pipeline card: 22 registered trials from official public datasets.Report a data error.